RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Free cash flow

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndFree cash flow (Million USD)YoY (%)
Dec 31, 20243,665-5.44%
Dec 31, 20233,875-12.42%
Dec 31, 20224,425-32.23%
Dec 31, 20216,529+225.90%
Dec 31, 20202,004+0.15%
Dec 31, 20192,000+10.40%
Dec 31, 20181,812+75.16%
Dec 31, 20171,034+7.60%
Dec 31, 2016961+47.27%
Dec 31, 2015653+59.17%
Dec 31, 2014410-4.02%
Dec 31, 2013427-444.75%
Dec 31, 2012-124-37.68%
Dec 31, 2011-199+5846.16%
Dec 31, 2010-3

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)